Home/Pipeline/VX-880

VX-880

Type 1 Diabetes

Phase 1/2Active

Key Facts

Indication

Type 1 Diabetes

Phase

Phase 1/2

Status

Active

Company

Vertex Pharmaceuticals

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a premier biotechnology company that has revolutionized treatment for cystic fibrosis with its portfolio of CFTR modulators, generating billions in annual revenue. The company has successfully expanded beyond CF into gene editing with CTX001 for sickle cell disease and beta thalassemia, and is advancing programs in pain, diabetes, and other serious diseases. With a strong commercial franchise and robust pipeline, Vertex represents one of the most successful biotech companies in translating scientific innovation into life-changing medicines.

View full company profile

Therapeutic Areas

Cystic Fibrosis Sickle Cell Disease Beta Thalassemia Pain Management Diabetes Kidney Disease

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
VCTX210 (Vertex collab.)	CRISPR Therapeutics	Phase 1/2	Clinical
UP421	Sana Biotechnology	Pre-Clinical	Active
SC451	Sana Biotechnology	Pre-Clinical	Active
BioVascular Pancreas™	Humacyte	Preclinical	Not Specified
ORMD-0801	Oramed Pharmaceuticals	Phase 2	Completed
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research